Top

European Radiology

Published in:

Open Access 01-05-2021 | Prostate Cancer | Oncology

The prevalence and locations of bone metastases using whole-body MRI in treatment-naïve intermediate- and high-risk prostate cancer

Authors: Fredrik Ottosson, Eduard Baco, Peter M. Lauritzen, Erik Rud

Published in: European Radiology | Issue 5/2021

Abstract

Objective

The aim of this study was to assess the prevalence and distribution of bone metastases in treatment-naïve prostate cancer patients eligible for a metastatic workup using whole-body MRI, and to evaluate the results in light of current guidelines.

Methods

This single-institution, retrospective study included all patients with treatment-naïve prostate cancer referred to whole-body MRI during 2016 and 2017. All were eligible for a metastatic workup according to the guidelines: PSA > 20 ng/ml and/or Gleason grade group ≥ 3 and/or cT ≥ 2c and/or bone symptoms. The definition of a metastasis was descriptive and based on the original MRI reports. The anatomical location of metastases was registered.

Results

We included 161 patients with newly diagnosed prostate cancer of which 36 (22%) were intermediate-risk and 125 (78%) were high-risk. The median age and PSA were 71 years (IQR 64–76) and 13 ng/ml (IQR 8–28), respectively. Bone metastases were found in 12 patients (7%, 95% CI: 4–13), and all were high-risk with Gleason grade group ≥ 4. The pelvis was affected in 4 patients, and the spine + pelvis in the remaining 8. No patients demonstrated metastases to the spine without concomitant metastases in the pelvis. Limitations are the small number of metastases and retrospective design.

Conclusion

This study suggests that the overall prevalence of bone metastases using the current guidelines for screening is quite low. No metastases were seen in the case of Gleason grade group ≤ 3, and further studies should investigate if it necessary to screen non-high-risk patients.

Key Points

• The overall prevalence of bone metastases was 7% in the case of newly diagnosed intermediate- and high-risk prostate cancer.

• The prevalence in high-risk patients was 10%, and no metastases were seen in patients with Gleason grade group ≤ 3.

• The pelvic skeleton is the main site, and no metastases occurred in the spine without concomitant pelvic metastases.

Mottet N, Bellmunt J, Bolla M et al (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent. Eur Urol 71:618–629. https://doi.org/10.1016/j.eururo.2016.08.003CrossRefPubMed

Heidenreich A, Bastian PJ, Bellmunt J et al (2013) EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol. https://doi.org/10.1016/j.eururo.2013.09.046

Shen G, Deng H, Hu S, Jia Z (2014) Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis. Skeletal Radiol 43:1503–1513. https://doi.org/10.1007/s00256-014-1903-9

Johnston EW, Latifoltojar A, Sidhu HS et al (2019) Multiparametric whole-body 3.0-T MRI in newly diagnosed intermediate- and high-risk prostate cancer: diagnostic accuracy and interobserver agreement for nodal and metastatic staging. Eur Radiol 29:3159–3169. https://doi.org/10.1007/s00330-018-5813-4CrossRefPubMed

Pasoglou V, Larbi A, Collette L et al (2014) One-step TNM staging of high-risk prostate cancer using magnetic resonance imaging (MRI): toward an upfront simplified “all-in-one” imaging approach? Prostate 74:469–477. https://doi.org/10.1002/pros.22764CrossRefPubMed

Trabulsi EJ, Rumble RB, Jadvar H, et al (2020) Optimum imaging strategies for advanced prostate cancer: ASCO Guideline. J Clin Oncol 38(17):1963–1996. https://doi.org/10.1200/JCO.19.02757

Bubendorf L, Schöpfer A, Wagner U et al (2000) Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 31:578–583. https://doi.org/10.1053/hp.2000.6698CrossRefPubMed

Batson OV (1940) The function of the vertebral veins and their role in the spread of metastases. Ann Surg 112:138–149. https://doi.org/10.1097/00000658-194007000-00016CrossRefPubMedPubMedCentral

Larbi A, Dallaudière B, Pasoglou V et al (2016) Whole body MRI (WB-MRI) assessment of metastatic spread in prostate cancer: therapeutic perspectives on targeted management of oligometastatic disease. Prostate 76:1024–1033. https://doi.org/10.1002/pros.23196CrossRefPubMed

10.

Lecouvet FE, Simon M, Tombal B, Jamart J, Vande Berg BC, Simoni P (2010) Whole-body MRI (WB-MRI) versus axial skeleton MRI (AS-MRI) to detect and measure bone metastases in prostate cancer (PCa). Eur Radiol 20:2973–2982. https://doi.org/10.1007/s00330-010-1879-3

11.

Baco E, Ukimura O, Rud E et al (2014) Magnetic resonance imaging-transrectal ultrasound image-fusion biopsies accurately characterize the index tumor: correlation with step-sectioned radical prostatectomy specimens in 135 patients. Eur Urol. https://doi.org/10.1016/j.eururo.2014.08.077

12.

Vargas HA, Schor-Bardach R, Long N et al (2017) Prostate cancer bone metastases on staging prostate MRI: prevalence and clinical features associated with their diagnosis. Abdom Radiol (NY) 42:271–277. https://doi.org/10.1007/s00261-016-0851-3CrossRef

13.

Ayyathurai R, Mahapatra R, Rajasundaram R, Srinivasan V, Archard NP, Toussi H (2006) A study on staging bone scans in newly diagnosed prostate cancer. Urol Int 76:209–212. https://doi.org/10.1159/000091620

14.

Abuzallouf S, Dayes I, Lukka H (2004) Baseline staging of newly diagnosed prostate cancer: a summary of the literature. J Urol 171:2122–2127. https://doi.org/10.1097/01.ju.0000123981.03084.06CrossRefPubMed

15.

Briganti A, Passoni N, Ferrari M et al (2010) When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool. Eur Urol 57:551–558. https://doi.org/10.1016/j.eururo.2009.12.023CrossRefPubMed

16.

Lengana T, Lawal IO, Boshomane TG et al (2018) 68Ga-PSMA PET/CT replacing bone scan in the initial staging of skeletal metastasis in prostate cancer: a fait accompli? Clin Genitourin Cancer 16:392–401. https://doi.org/10.1016/j.clgc.2018.07.009CrossRefPubMed

17.

O’Sullivan JM, Norman AR, Cook GJ, Fisher C, Dearnaley DP (2003) Broadening the criteria for avoiding staging bone scans in prostate cancer: a retrospective study of patients at the Royal Marsden Hospital. BJU Int 92:685–689. https://doi.org/10.1046/j.1464-410x.2003.04480.x

18.

Jacobson AF (2000) Association of prostate-specific antigen levels and patterns of benign and malignant uptake detected. On bone scintigraphy in patients with newly diagnosed prostate carcinoma. Nucl Med Commun 21:617–622. https://doi.org/10.1097/00006231-200007000-00003CrossRefPubMed

19.

Kvåle R, Møller B, Wahlqvist R et al (2009) Concordance between Gleason scores of needle biopsies and radical prostatectomy specimens: a population-based study. BJU Int 103:1647–1654. https://doi.org/10.1111/j.1464-410X.2008.08255.xCrossRefPubMed

20.

Fine SW, Epstein JI (2008) A contemporary study correlating prostate needle biopsy and radical prostatectomy Gleason score. J Urol 179:1335–1338– discussion 1338–9. https://doi.org/10.1016/j.juro.2007.11.057CrossRefPubMed

21.

Rud E, Klotz D, Rennesund K et al (2014) Preoperative magnetic resonance imaging for detecting uni- and bilateral extraprostatic disease in patients with prostate cancer. World J Urol 33:1015–1021. https://doi.org/10.1007/s00345-014-1362-xCrossRefPubMedPubMedCentral

22.

Woo S, Kim SY, Kim SH, Cho JY (2016) JOURNAL CLUB: identification of bone metastasis with routine prostate MRI: a study of patients with newly diagnosed prostate cancer. AJR Am J Roentgenol 206:1156–1163. https://doi.org/10.2214/AJR.15.15761CrossRefPubMed

23.

Cumming J, Hacking N, Fairhurst J, Ackery D, Jenkins JD (1990) Distribution of bony metastases in prostatic carcinoma. Br J Urol 66:411–414. https://doi.org/10.1111/j.1464-410x.1990.tb14964.x

24.

Larbi A, Omoumi P, Pasoglou V et al (2018) Whole-body MRI to assess bone involvement in prostate cancer and multiple myeloma: comparison of the diagnostic accuracies of the T1, short tau inversion recovery (STIR), and high b-values diffusion-weighted imaging (DWI) sequences. Eur Radiol 37:1077–1011. https://doi.org/10.1007/s00330-018-5796-1CrossRef

25.

Lecouvet FE, Pasoglou V, Van Nieuwenhove S et al (2020) Shortening the acquisition time of whole-body MRI: 3D T1 gradient echo Dixon vs fast spin echo for metastatic screening in prostate cancer. Eur Radiol 23:123–111. https://doi.org/10.1007/s00330-019-06515-yCrossRef

26.

Maeder Y, Dunet V, Richard R, Becce F, Omoumi P (2018) Bone marrow metastases: T2-weighted Dixon spin-echo fat images can replace T1-weighted spin-echo images. Radiology 286:948–959. https://doi.org/10.1148/radiol.2017170325

27.

Padhani AR, Lecouvet FE, Tunariu N et al (2017) METastasis reporting and data system for prostate cancer: practical guidelines for acquisition, interpretation, and reporting of whole-body magnetic resonance imaging-based evaluations of multiorgan involvement in advanced prostate cancer. Eur Urol 71:81–92. https://doi.org/10.1016/j.eururo.2016.05.033CrossRefPubMedPubMedCentral

28.

Parker CC, James ND, Brawley CD et al (2018) Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 392:2353–2366. https://doi.org/10.1016/S0140-6736(18)32486-3CrossRefPubMedPubMedCentral

Title: The prevalence and locations of bone metastases using whole-body MRI in treatment-naïve intermediate- and high-risk prostate cancer
Authors: Fredrik Ottosson
Eduard Baco
Peter M. Lauritzen
Erik Rud
Publication date: 01-05-2021
Publisher: Springer Berlin Heidelberg
Keywords: Prostate Cancer
Magnetic Resonance Imaging
Magnetic Resonance Imaging
Metastasis
Prostate Cancer
Published in: European Radiology / Issue 5/2021
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-020-07363-x

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

The prevalence and locations of bone metastases using whole-body MRI in treatment-naïve intermediate- and high-risk prostate cancer

Abstract

Objective

Methods

Results

Conclusion

Key Points

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Key Points

Please log in to get access to this content

Other articles of this Issue 5/2021

Predictive factors of severe abdominal pain during and after transarterial chemoembolization for hepatocellular carcinoma

Prospective study of Lipiodol distribution as an imaging marker for doxorubicin pharmacokinetics during conventional transarterial chemoembolization of liver malignancies

Meta-analysis of CT and MRI for differentiation of autoimmune pancreatitis from pancreatic adenocarcinoma

Cocaine use worsens coronary atherosclerosis in HIV infected

The sensitivity and specificity of chest CT in the diagnosis of COVID-19

Histological validation of simultaneous non-contrast angiography and intraplaque hemorrhage imaging (SNAP) for characterizing carotid intraplaque hemorrhage